'Cancer Moonshot' Projects Funded Include Implant to Sense and Treat Cancer, Tumor-Targetting Bacteria

Researchers from several U.S. institutions are collaborating "to develop and test an implantable device able to sense signs of the kind of inflammation associated with cancer," reports CBS News, "and delivery therapy when needed."Northwestern said the implant could significantly improve outcomes for patients with ovarian, pancreatic and other difficult-to-treat cancers - potentially cutting cancer-related deaths in the U.S. in half. "Instead of tethering patients to hospital beds, IV bags and external monitors, we'll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time," said Rice University bioengineer Omid Veiseh. "This kind of 'closed-loop therapy' has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it's revolutionary." The project and team are named THOR, an acronym for "targeted hybrid oncotherapeutic regulation..." explains an announcement from Johns Hopkins. "THOR's proposed implant, or 'hybrid advanced molecular manufacturing regulator,' goes by the acronym HAMMR..." The project will take five and a half years, and includes funding for a first-phase clinical trial treating recurrent ovarian cancer slated to begin in the fourth year. The research is funded by America's newly-established Advanced Research Projects Agency for Health (ARPA-H), according to a statement from the agency, representing its "commitment to supporting Cancer Moonshot goals of decreasing cancer deaths and improving the quality of life for patients..." And they're also funding two more projects:The Synthetic Programmable bacteria for Immune-directed Killing in tumor Environments (SPIKEs) project, led by a team at the University of Missouri in Columbia, Missouri, aims to develop an inexpensive and safe therapy using bacteria specifically selected for tumor-targeting. Through SPIKEs, researchers intend to engineer bacteria that can recruit and regulate tumor-targeting immune cells, boosting the body's ability to fight off cancer without side-effects from traditional medications. Up to $19 million is allocated towards SPIKEs. An additional project, with up to $50 million in potential funding inclusive of options, seeks to map cancer cell biomarkers to drastically improve multi-cancer early detection (MCED) and streamline clinical intervention when tumors are still small. Led by the Georgia Institute of Technology in Atlanta, Georgia, the Cancer and Organ Degradome Atlas (CODA) project aims to understand the cellular profiles unique to diseased cancer cells. The CODA platform intends to develop a suite of biosensor tools that can reliably recognize a range of cancer-specific markers and, ultimately, produce a highly precise, accurate, and cost-effective MCED test that can identify common cancers when they are most treatable. In a statement, ARPA-H's director said that "With these awards, we hope to see crucial advancements in patient-tailored therapies, better and earlier tumor detection methods, and cell therapies that can help the immune system target cancer cells for destruction."

Read more of this story at Slashdot.